Phosphodiesterase-5 inhibitors for male erectile dysfunction

Bibliography

• BROCK G: Oral agents: first-line therapy for erectile dysfunction. Eur. Urol. Stipp] (2002) 1:12–18.
   Web of Science ®Google Scholar
• GRESSER U, GLEITER CH: Erectile dysfunction: comparison of efficacy and side effects of the PDE5 inhibitors sildenafil, vardenafil and tadalafil, review of the literature. Eur. J. Med. Res. (2002) 7:435–446.
   PubMed Web of Science ®Google Scholar
• •Provides a comparison of the three launched PDE5 inhibitors.
   Google Scholar
• BEAVO JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev (1995) 75:725–748.
   PubMed Web of Science ®Google Scholar
• SODERLING SH, BEAVO JA: Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curc Opin. Cell Biol. (2000) 12:174–179.
   PubMed Web of Science ®Google Scholar
• FAWCETT L, BAXENDALE R, STACEY P et al.: Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc. Nail. Acad. Sci. USA (2000) 97:3702–3707.
   PubMed Web of Science ®Google Scholar
• BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenalfil: an orally-active Type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. hat. hnpot. Res. (1996) 8:47–52.
   PubMedGoogle Scholar
• CORBIN J, FRANCIS S: Cyclic GMP phosphodiesterases-5: target of sildenafil. Biol. Chem. (1999) 274:13729–13732.
   Web of Science ®Google Scholar
• •Provides biological information on PDE5 at the molecular level.
   Google Scholar
• STAMFORD AW: Phosphodiesterase 5 inhibitors. Ann. Reports Med. Chem. (2002) 37:53–64.
   Web of Science ®Google Scholar
• ••A medicinal chemistry review that iscomplimentary to this review.
   Google Scholar
• ROTELLA DP: Phosphodiesterase-5 inhibitors: current status and potential applications. Nat. Rev Drug Discov. (2002) 1:674–682.
   PubMed Web of Science ®Google Scholar
• ROTELLA D: Phosphodiesterase Type 5 inhibitors: discovery and therapeutic utility. Drugs Future (2001) 26:153–162.
   Web of Science ®Google Scholar
• STIEF CG: Phosphosdiesterase inhibitors in the treatment of erectile dysfunction. Drugs Today (2000) 36(2-3):93–99.
   PubMed Web of Science ®Google Scholar
• KOTHE A, MONTORSI F, ANDERSON KE, STIEF CG: Phosphodiesterase inhibitors for the treatment of erectile dysfunction. Curt: Opin. Invest. Drugs (2002) 3(10489–1495.
   Google Scholar
• GINGELL JC, LOCKYER R: Emerging pharmacological therapies for erectile dysfunction. Expert Opin. Ther. Patents (1999) 9:1689–1696.
   Web of Science ®Google Scholar
• SHIM, HJ, LEE EJ, JUNG YH et al.: Determination of a new phosphodiesterase V inhibitor, DA-8159, in plasma and urine by high-performance liquid chromatography. .1. Pharm. Biomed. Anal. (1999) 30:527–533.
   Google Scholar
• KIM DK, LEE JY, LEE Net al.: Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring. Biorg. Med. Chem. Lett. (2001) 9:3013–3021.
   Google Scholar
• KIM DK, RYU DH, LEE N et al.: Synthesis and phosphodiesterase inhibitory activity of new 5-pheny1-1,6-dihydro-7H-pyrazolo [4,3-d] pyrimidin-7-one derivatives containing an N-acylamino group on a phenyl ring. Biorg. Med. Chem. Lett. (2001) 9:1895–1899.
   Google Scholar
• HANING H, NIEWOHNER U, SCHENKE T et al: Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE5 inhibitors, Bioorg. Med. Chem. Lett. (2002) 12:865–868.
   PubMed Web of Science ®Google Scholar
• ABEL S, BEAUMONT KC, CRESPI CL et al.: Potential role for P-glycoprotein in the non-proportional pharmacolkinetics of UK-343664 in man. Xenobiotica (2001) 31(819):665–676.
   PubMedGoogle Scholar
• WALKER DK, BEAUMONT KC, COMBY P et al.: Pharmacolkinetcs and metabolism of a selective PDE5 inhibitor (UK-343664) in rat and dog. Xenobiotica (2001) 31(8/9):651–664.
   Google Scholar
• ARNOLD R, BEER D, BHALAY Get al.: 8-Aryl xanthines potent inhibitors of phosphodiesterase 5. Bioorg. Med. Chem. Lett. (2002) 12:2587–2590.
   Google Scholar
• YU G, MASON HJ, WU X et al: Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. J. Med. Chem. (2001) 44:1025–1027.
   PubMed Web of Science ®Google Scholar
• SUI Z, GUAN J, MACIELAG M, JIANG W: Synthesis and biological activities of novel I3-carboline as PDE5 inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:761–765.
   PubMedGoogle Scholar
• WATANABE N, KABASAWA Y, TAKASE Y et al.: 4-Benylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase-5. j Med. Chem. (1998) 41:3367–3372.
   PubMed Web of Science ®Google Scholar
• WATANABE N, ADACHI Y, TAKASE Y et al.: 4- (3-Choloro-4-methoxybenzyl) aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase. J. Med. Chem. (2000) 43:2523–2529.
   PubMed Web of Science ®Google Scholar
• YU G, MASON H, WU X et at Substituted pyrazolopyridopyridazines as orally-bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. J. Med. Chem. (2003) 46:457–460.
   PubMed Web of Science ®Google Scholar
• SUI Z, GUAN J, MACIELAG M et al.: Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction. J. Med. Chem. (2002) 45:4094–4096.
   PubMed Web of Science ®Google Scholar
• JIANG W, SUI Z, MACIELAG M et al: Furoyl pyrroloquinolones as selective PDE5 inhibitors. J. Med. Chem. (2003) 46:441–444.
   PubMed Web of Science ®Google Scholar
• LANTER J, SUI Z, MACIELAG M et al.: Structure-activity relationships of N-acyl pyrroloquinolone PDE5 inhibitors. (submitted).
   Google Scholar
• ROTELLA D, SUN Z, ZHU Y et aL: N-3-substituted imidazoquinolones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. Med. Chem. (2000) 43:1257–1263.
   Web of Science ®Google Scholar
• BI Y, STORY P, ADAM L et al: The discovery of novel, potent and selective PDE5 inhibitors. Bioorg. Med. Chem. Lett. (2001) 11:2461–2464.
   PubMed Web of Science ®Google Scholar
• UKITA T, NAKAMURA Y, KUBO A et al: 1-Arylnaphthalene lignan: a novel scaffold for Type 5 phosphodiesterase inhibitor. J. Med. Chem. (1999) 42:1293–1305.
   PubMed Web of Science ®Google Scholar
• UKITA T, NAKAMURA Y, KUBO A et al.: Novel, potent, and selective phosphodiesterase-5 inhibitors: synthesis and biological activities of a series of 4-ary1-1-isoquinolinone derivatives. .1. Med. Chem. (2001) 44:2204–2218.
   Google Scholar
• SHIN HJ, KIM HJ, KWAK JH et al.: A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase-5. Bioorg. Med. Chem. Lett. (2002) 12:2313–2316.
   PubMed Web of Science ®Google Scholar